Adderall

Clinical Pharmacology

Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of
therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Amphetamines are
thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.

Pharmacokinetics

ADDERALL® tablets contain d-amphetamine and l-amphetamine salts in the ratio of 3:1. Following
administration of a single dose 10 or 30 mg of ADDERALL® to healthy volunteers under fasted conditions,
peak plasma concentrations occurred approximately 3 hours post-dose for both d-amphetamine and lamphetamine.

The mean elimination half-life (t1/2) for d-amphetamine was shorter than the t1/2 of the l-isomer
(9.77-11 hours vs. 11.5-13.8 hours). The PK parameters (Cmax, AUC0-inf) of d-and l-amphetamine increased approximately three-fold from 10 mg to 30 mg indicating dose-proportional pharmacokinetics.
The effect of food on the bioavailability of ADDERALL® has not been studied.
Metabolism and Excretion:

Click here for FDA